GLA Mutation Chaperone Therapy for Stable α-Gal A Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Fabry disease, such as enzyme replacement therapy (ERT), face challenges including rapid degradation of infused proteins, high costs, difficulties in protein purification and storage, generation of anti-protein immune responses, and inability to cross the blood-brain barrier, making it difficult to predict patient responsiveness to pharmacological chaperones (PCs) due to varied GLA mutations.
Innovation Solution
Administering a therapeutically effective dose of migalastat or its salt, a pharmacological chaperone, to patients with specific missense mutations in the α-Gal A gene, such as D33H, G35A, Y88S, T194A, W204G, Y216S, Q250K, or R392T, to stabilize and enhance the activity of mutant α-Gal A enzymes, allowing them to traffic out of the ER and reduce substrate accumulation in tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy (ERT) is used to treat Fabry disease, then substrate accumulation can be reduced, but the infused protein is rapidly degraded requiring numerous high dose infusions
Solution Approach 1:
Pharmacological chaperones act as intermediary molecules that bind to mutant α-Gal A enzymes, stabilizing their conformation and protecting them from degradation. This mediator approach allows the endogenous enzyme to function longer without requiring frequent exogenous protein infusions, directly addressing the rapid degradation issue of ERT
Solution Approach 2:
The patent changes the physical-chemical parameters of the enzyme by introducing small molecule pharmacological chaperones that alter the conformational stability and trafficking properties of mutant α-Gal A. This parameter change enables the enzyme to resist degradation and reach its functional destination, extending its duration of action
2Reliability
If enzyme replacement therapy (ERT) is used to treat Fabry disease, then substrate accumulation can be reduced, but high costs are incurred due to numerous costly high dose infusions
Solution Approach 1:
Pharmacological chaperones serve as cost-effective intermediary small molecules compared to expensive recombinant protein therapies. By using these small molecule mediators to stabilize endogenous enzymes, the treatment achieves sustained enzyme activity without the high recurring costs of repeated protein infusions
Solution Approach 2:
The patent employs small molecule pharmacological chaperones that are chemically stable, easy to manufacture, and significantly cheaper than recombinant protein therapies. These small molecules provide sustained therapeutic effect without the high production, purification, and storage costs associated with protein-based ERT
3Reliability
If enzyme replacement therapy (ERT) is used to treat Fabry disease, then substrate accumulation can be reduced, but difficulties arise in large-scale generation, purification, and storage of properly folded protein
Solution Approach 1:
Pharmacological chaperones act as molecular mediators that simplify manufacturing by working with endogenous enzymes rather than requiring complex production of purified recombinant proteins. The small molecules are chemically synthesized with straightforward purification and storage requirements, eliminating the manufacturing complexities of protein-based therapies
Solution Approach 2:
The patent replaces complex protein manufacturing with simple small molecule synthesis. These chemical compounds are stable, easy to produce at scale, and require minimal purification and storage conditions compared to labile recombinant proteins, dramatically improving ease of manufacture
4Reliability
If enzyme replacement therapy (ERT) is used to treat Fabry disease, then substrate accumulation can be reduced, but generation of anti-protein immune response occurs
Solution Approach 1:
The patent replaces protein-based therapy with small molecule pharmacological chaperones that are not immunogenic. These small molecules do not trigger anti-protein immune responses, eliminating the harmful immune reactions while maintaining sustained enzyme activity through chaperone-mediated stabilization of endogenous enzymes
5Reliability
If enzyme replacement therapy (ERT) is used to treat Fabry disease, then substrate accumulation can be reduced, but protein cannot cross the blood-brain barrier to mitigate central nervous system pathologies
Solution Approach 1:
Pharmacological chaperones serve as lipophilic intermediary molecules that can cross the blood-brain barrier via passive diffusion or transport mechanisms. Once inside the CNS, they stabilize endogenous mutant enzymes, delivering therapeutic effect to the central nervous system without the bioavailability limitations of large protein molecules
6Reliability
If enzyme replacement therapy (ERT) is used to treat Fabry disease, then substrate accumulation can be reduced, but replacement enzyme cannot penetrate the heart or kidney in sufficient amounts to reduce substrate accumulation in renal podocytes or cardiac myocytes
Solution Approach 1:
Pharmacological chaperones act as molecular mediators with optimal pharmacokinetic properties including appropriate molecular size, lipophilicity, and stability. These properties enable them to penetrate heart and kidney tissues effectively, reaching renal podocytes and cardiac myocytes to stabilize endogenous enzymes and reduce substrate accumulation in these critical organs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances α-Gal A activity in patients with identified mutations, leading to reduced substrate accumulation and amelioration of Fabry disease symptoms, including improvements in cardiac and renal function, and neurological symptoms, through increased enzyme stability and trafficking.
Implementation Method 1
administering a therapeutically effective dose of migalastat or its salt, a pharmacological chaperone, to patients with specific missense mutations in the α-Gal A gene... to stabilize and enhance the activity of mutant α-Gal A enzymes
Data Source
AI summary
Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing α-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for α-galactosidase A, wherein the patient has a mutation in the nucleic acid sequence encoding α-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.